Constantiam Biosciences
Constantiam Biosciences is dedicated to accelerating the development of life-saving precision diagnostics and therapeutics by elucidating the consequences of human genetic variation. They specialize in integrating massively multiplexed functional genomics experiments with human biobank data using probabilistic machine learning, aiming to power genomic medicine and improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
Constantiam Biosciences
https://www.constantiambio.com/contact/
Products
Functional evidence repository and reporting service
A searchable resource that aggregates curated functional assay data, ranks assays by performance, calibrates functional scores to clinical evidence levels, and produces concise reports for each variant.
High-throughput variant functional screening and drug-response profiling
Experimental service to measure variant-specific functional effects and drug sensitivity across thousands of variants in a single experiment, combined with computational models to predict clinical responsiveness.
Target identification and prioritization platform
Integrated computational and experimental workflow that uses human genetic evidence and functional validation to rank and prioritize therapeutic targets for development.
Clinical trial enrichment analytics (variant-based)
Analytics service providing drug-sensitivity profiles and predicted patient response probabilities derived from drug-specific functional scans to inform trial eligibility and enrichment.
Functional evidence repository and reporting service
A searchable resource that aggregates curated functional assay data, ranks assays by performance, calibrates functional scores to clinical evidence levels, and produces concise reports for each variant.
High-throughput variant functional screening and drug-response profiling
Experimental service to measure variant-specific functional effects and drug sensitivity across thousands of variants in a single experiment, combined with computational models to predict clinical responsiveness.
Target identification and prioritization platform
Integrated computational and experimental workflow that uses human genetic evidence and functional validation to rank and prioritize therapeutic targets for development.
Clinical trial enrichment analytics (variant-based)
Analytics service providing drug-sensitivity profiles and predicted patient response probabilities derived from drug-specific functional scans to inform trial eligibility and enrichment.
Services
Provision of a centralized, curated database of high-throughput functional assay results, independent assay evaluation, calibrated evidence scoring, and generation of concise variant reports for clinical use.
Experimental design and execution of high-throughput cellular assays combined with Bayesian modeling to classify variants, predict drug responsiveness, and expand diagnosable patient populations.
Integrated experimental and computational workflows that combine human genetic association data with multiplexed functional validation and machine learning to prioritize therapeutic targets.
Provision of drug-specific variant sensitivity profiles and probability-of-response estimates to inform clinical trial inclusion criteria and enrichment strategies.
Provision of a centralized, curated database of high-throughput functional assay results, independent assay evaluation, calibrated evidence scoring, and generation of concise variant reports for clinical use.
Experimental design and execution of high-throughput cellular assays combined with Bayesian modeling to classify variants, predict drug responsiveness, and expand diagnosable patient populations.
Integrated experimental and computational workflows that combine human genetic association data with multiplexed functional validation and machine learning to prioritize therapeutic targets.
Provision of drug-specific variant sensitivity profiles and probability-of-response estimates to inform clinical trial inclusion criteria and enrichment strategies.
Expertise Areas
- Functional genomics (multiplexed assays / MAVEs)
- Clinical variant interpretation and VUS resolution
- Machine learning and probabilistic modeling for genomics
- Target discovery and prioritization from human genetics
Key Technologies
- Massively multiplexed assays of variant effect (MAVEs / Deep Mutational Scanning)
- Probabilistic / Bayesian machine learning
- Base editing and prime editing (genome editing for screens)
- Next-generation sequencing (NGS) data handling
News & Updates
OHSU’s newsletter highlights Constantiam’s agreement to license data from Dr. Brian O’Roak’s lab.
Story of tennis legend Chris Evert’s battle with ovarian cancer, genetic testing, and early detection.
Overview of Multiplexed Assays of Variant Effect (MAVEs) and their application in clinical variant interpretation.
Explains MAVEs as functional evidence for genetic variant classification within the ACMG/AMP framework.
Discusses how MAVEs can help early detection of breast cancer, especially in BRCA1/2 genes.
OHSU’s newsletter highlights Constantiam’s agreement to license data from Dr. Brian O’Roak’s lab.
Story of tennis legend Chris Evert’s battle with ovarian cancer, genetic testing, and early detection.
Overview of Multiplexed Assays of Variant Effect (MAVEs) and their application in clinical variant interpretation.
Explains MAVEs as functional evidence for genetic variant classification within the ACMG/AMP framework.
Discusses how MAVEs can help early detection of breast cancer, especially in BRCA1/2 genes.